查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464274

英國勃起功能障礙市場 - 產業趨勢與預測（~2031 年）

U.K. Erectile Dysfunction Market - Industry Trends and Forecast to 2031
出版日期: | 出版商: Data Bridge Market Research | 英文 106 Pages | 商品交期: 請詢問到貨日

價格

英國勃起功能障礙市場規模預計將從 2023 年的 2.6049 億美元增至 2031 年的 4.5163 億美元，預計 2024-2031 年的複合年增長率為 7.2%。

本報告研究和分析了英國勃起功能障礙市場，提供行業趨勢和預測、驅動和限制因素以及公司趨勢等資訊。

目錄

第一章簡介

第二章市場區隔

第 3 章執行摘要

第 4 章重要考量

  • PESTEL 分析
  • 波特五力分析模型
  • 供應商佔有率分析
  • 品牌分析
    • 主要品牌
    • 品牌定位
    • 市場滲透率
    • 競爭對手分析
  • 消費者洞察
    • 人口統計因素
    • 心理概況
    • 消費者偏好
    • 購買行為
    • 影響購買決策的因素
  • 績效分析
    • 趨勢分析
  • 零售分析

第五章市場概論

  • 促進因素
    • 慢性病流行
    • 久坐的生活方式和相關壓力增加
    • 主要市場參與者推出更多新產品
    • 提高病人對醫療狀況和藥物的認識
  • 抑制因素
    • 對審批的監理限制
    • 勃起功能障礙治療費用高
  • 機會
    • 處方藥及其仿製藥的供應情況
    • 不斷進步的科技進步
    • 啟動研發
  • 作業
    • 與勃起功能障礙治療藥物相關的各種副作用
    • 缺乏熟練的專業人員

第 6 章英國勃起功能障礙市場：依產品類型

  • 摘要
  • 醫學
    • 口腔醫學
    • 外用製劑
    • 陰莖注射
    • 栓劑
  • 設備
    • 陰莖幫浦/真空收縮裝置
    • 陰莖植入物
    • 衝擊波療法

第 7 章英國勃起功能障礙市場：依類型

  • 摘要
  • 繼發性勃起功能障礙
  • 原發性勃起功能障礙

第 8 章英國勃起功能障礙市場：依年齡組別劃分

  • 摘要
  • 40歲以下
  • 40-60歲
  • 60歲以上

第 9 章英國勃起功能障礙市場：依最終使用者劃分

  • 摘要
  • 醫院
  • 專科診所
  • 家庭醫療護理
  • 門診手術中心
  • 其他

第 10 章英國勃起功能障礙市場：依通路劃分

  • 摘要
  • 直接提供
  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

第 11 章英國勃起功能障礙市場：公司狀況

  • 公司股票分析：全球

第十二章 SWOT 分析

第十三章公司簡介

  • PFIZER INC.
  • LUPIN
  • COLOPLAST CORP
  • VIATRIS INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • AUGUSTA MEDICAL SYSTEMS
  • BAYER AG
  • BOSTON SCIENTIFIC CORPORATION
  • ELI LILY AND COMPANY
  • RIGICON, INC.
  • ZEPHYR SURGICAL IMPLANTS.

第 14 章調查

第15章相關報告

U.K. erectile dysfunction market is expected to reach USD 451.63 million by 2031, from USD 260.49 million in 2023 growing at the CAGR of 7.2% in the forecast period of 2024 to 2031.

Market Segmentation

U.K. Erectile Dysfunction Market, By Product Type (Drugs and Devices), Type (Secondary Erectile Dysfunction and Primary Erectile Dysfunction), Age Group (Less than 40, 40-60 and 60 - Above), End User (Hospital, Specialty Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tenders, Retail Pharmacy, Online Pharmacy, Hospital Pharmacy and Others) - Industry Trends and Forecast to 2031

Overview of U.K. Erectile Dysfunction Market Dynamics

  • Driver
  • Rising prevalence of chronic diseases
  • Restraint
  • Regulatory constraints for approval
  • Opportunity
  • Availability of prescription medication and its generic version

Market Players

Some of the key market players for U.K. erectile dysfunction market are:

  • Lupin
  • Teva Pharmaceutical Industries Ltd.
  • Augusta Medical Systems
  • Boston Scientific Corporation
  • Coloplast Corp
  • Rigicon, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Eli Lily and Company
  • Viatris Inc.
  • ZSI, Zephyr Surgical Implants

TABLE OF CONTENTS

1 INTRODUCTION 11

  • 1.1 OBJECTIVES OF THE STUDY 11
  • 1.2 MARKET DEFINITION 11
  • 1.3 OVERVIEW OF U.K. ERECTILE DYSFUNCTION MARKET 11
  • 1.4 CURRENCY AND PRICING 12
  • 1.5 LIMITATIONS 12
  • 1.6 MARKETS COVERED 13

2 MARKET SEGMENTATION 15

  • 2.1 MARKETS COVERED 15
  • 2.2 GEOGRAPHICAL SCOPE 16
  • 2.3 YEARS CONSIDERED FOR THE STUDY 16
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 17
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
  • 2.6 MULTIVARIATE MODELLING 21
  • 2.7 MARKET END USER COVERAGE GRID 22
  • 2.8 PRODUCT LIFELINE CURVE 23
  • 2.9 DBMR MARKET POSITION GRID 24
  • 2.10 VENDOR SHARE ANALYSIS 25
  • 2.11 SECONDARY SOURCES 26
  • 2.12 ASSUMPTIONS 26

3 EXECUTIVE SUMMARY 27

4 PREMIUM INSIGHTS 29

  • 4.1 PESTEL ANALYSIS 30
  • 4.2 PORTER'S FIVE FORCES MODEL 31
  • 4.3 VENDOR SHARE ANALYSIS 32
  • 4.4 BRAND ANALYSIS 33
    • 4.4.1 LEADING BRANDS 33
    • 4.4.2 BRAND POSITIONING 33
    • 4.4.3 MARKET PENETRATION 34
    • 4.4.4 COMPETITIVE ANALYSIS 35
  • 4.5 CONSUMER INSIGHTS 36
    • 4.5.1 DEMOGRAPHIC INSIGHTS 36
    • 4.5.2 PSYCHOGRAPHIC PROFILE 36
    • 4.5.3 CONSUMER PREFERENCES 37
    • 4.5.4 PURCHASING BEHAVIOUR 37
    • 4.5.5 FACTORS INFLUENCING BUYING DECISION 37
  • 4.6 PERFORMANCE ANALYSIS 39
    • 4.6.1 TREND ANALYSIS 39
  • 4.7 RETAIL ANALYSIS 41

5 MARKET OVERVIEW 44

  • 5.1 DRIVERS 46
    • 5.1.1 RISING PREVALENCE OF CHRONIC DISEASES 46
    • 5.1.2 RISING ADOPTION OF SEDENTARY LIFESTYLE AND ASSOCIATED STRESS 46
    • 5.1.3 RISING PRODUCT LAUNCHES BY MAJOR MARKET PLAYERS 47
    • 5.1.4 RISING PATIENT AWARENESS REGARDING THE CONDITION AND MEDICATION 47
  • 5.2 RESTRAINTS 48
    • 5.2.1 REGULATORY CONSTRAINTS FOR APPROVAL 48
    • 5.2.2 HIGH COST OF ERECTILE DYSFUNCTION TREATMENT 48
  • 5.3 OPPORTUNITIES 49
    • 5.3.1 AVAILABILITY OF PRESCRIPTION MEDICATION AND ITS GENERIC VERSION 49
    • 5.3.2 RISING TECHNOLOGICAL ADVANCEMENTS 49
    • 5.3.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 50
  • 5.4 CHALLENGES 51
    • 5.4.1 VARIOUS SIDE EFFECTS ASSOCIATED WITH ERECTILE DYSFUNCTION DRUGS 51
    • 5.4.2 LACK OF SKILLED PROFESSIONALS 51

6 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE 52

  • 6.1 OVERVIEW 53
  • 6.2 DRUGS 56
    • 6.2.1 ORAL DRUGS 56
      • 6.2.1.1 BRANDED 57
        • 6.2.1.1.1 VIAGRA 57
        • 6.2.1.1.2 CIALIS 57
        • 6.2.1.1.3 LEVITRA 57
        • 6.2.1.1.4 AVANAFIL 57
        • 6.2.1.1.5 OTHERS 57
      • 6.2.1.2 GENERIC 57
    • 6.2.2 TOPICAL FORMULATION 58
    • 6.2.3 PENILE INJECTIONS 58
      • 6.2.3.1 PAPAVERINE 58
      • 6.2.3.2 PHENTOLAMINE 58
      • 6.2.3.3 PROSTAGLANDIN E1 (PGE1) 58
    • 6.2.4 SUPPOSITORIES 58
  • 6.3 DEVICES 59
    • 6.3.1 PENIS PUMPS/VACCUM CONSTRICTION DEVICES 59
      • 6.3.1.1 HAND-POWERED 59
      • 6.3.1.2 BATTERY-POWERED PUMP 59
    • 6.3.2 PENILE IMPLANTS 60
      • 6.3.2.1 SEMIRIGID/MALLEABLE 60
      • 6.3.2.2 INFLATABLE 60
    • 6.3.3 SHOCK WAVE THERAPY 60

7 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE 61

  • 7.1 OVERVIEW 62
  • 7.2 SECONDARY ERECTILE DYSFUNCTION 65
  • 7.3 PRIMARY ERECTILE DYSFUNCTION 65

8 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP 66

  • 8.1 OVERVIEW 67
  • 8.2 LESS THAN 40 70
  • 8.3 40-60 70
  • 8.4 60 AND ABOVE 70

9 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER 71

  • 9.1 OVERVIEW 72
  • 9.2 HOSPITALS 75
  • 9.3 SPECIALTY CLINICS 75
  • 9.4 HOME HEALTHCARE 75
  • 9.5 AMBULATORY SURGICAL CENTERS 75
  • 9.6 OTHERS 75

10 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL 76

  • 10.1 OVERVIEW 77
  • 10.2 DIRECT TENDERS 80
  • 10.3 HOSPITAL PHARMACY 80
  • 10.4 RETAIL PHARMACY 80
  • 10.5 ONLINE PHARMACY 80
  • 10.6 OTHERS 80

11 U.K. ERECTILE DYSFUNCTION MARKET, COMPANY LANDSCAPE 81

  • 11.1 COMPANY SHARE ANALYSIS: GLOBAL 81

12 SWOT ANALYSIS 82

13 COMPANY PROFILES 83

  • 13.1 PFIZER INC. 83
    • 13.1.1 COMPANY SNAPSHOT 83
    • 13.1.2 REVENUE ANALYSIS 83
    • 13.1.3 PRODUCT PORTFOLIO 84
    • 13.1.4 RECENT DEVELOPMENTS 84
  • 13.2 LUPIN 85
    • 13.2.1 COMPANY SNAPSHOT 85
    • 13.2.2 REVENUE ANALYSIS 85
    • 13.2.3 PRODUCT PORTFOLIO 86
    • 13.2.4 RECENT DEVELOPMENTS 86
  • 13.3 COLOPLAST CORP 87
    • 13.3.1 COMPANY SNAPSHOT 87
    • 13.3.2 REVENUE ANALYSIS 87
    • 13.3.3 PRODUCT PORTFOLIO 88
    • 13.3.4 RECENT DEVELOPMENTS 88
  • 13.4 VIATRIS INC. 89
    • 13.4.1 COMPANY SNAPSHOT 89
    • 13.4.2 REVENUE ANALYSIS 89
    • 13.4.3 PRODUCT PORTFOLIO 90
    • 13.4.4 RECENT DEVELOPMENTS 90
  • 13.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 91
    • 13.5.1 COMPANY SNAPSHOT 91
    • 13.5.2 REVENUE ANALYSIS 91
    • 13.5.3 PRODUCT PORTFOLIO 92
    • 13.5.4 RECENT DEVELOPMENTS 92
  • 13.6 AUGUSTA MEDICAL SYSTEMS 93
    • 13.6.1 COMPANY SNAPSHOT 93
    • 13.6.2 PRODUCT PORTFOLIO 93
    • 13.6.3 RECENT DEVELOPMENT 93
  • 13.7 BAYER AG 94
    • 13.7.1 COMPANY SNAPSHOT 94
    • 13.7.2 REVENUE ANALYSIS 94
    • 13.7.3 PRODUCT PORTFOLIO 95
    • 13.7.4 RECENT DEVELOPMENTS 95
  • 13.8 BOSTON SCIENTIFIC CORPORATION 96
    • 13.8.1 COMPANY SNAPSHOT 96
    • 13.8.2 REVENUE ANALYSIS 96
    • 13.8.3 PRODUCT PORTFOLIO 97
    • 13.8.4 RECENT DEVELOPMENTS 97
  • 13.9 ELI LILY AND COMPANY
    • 13.9.1 COMPANY SNAPSHOT 98
    • 13.9.2 REVENUE ANALYSIS 98
    • 13.9.3 PRODUCT PORTFOLIO 99
    • 13.9.4 RECENT DEVELOPMENTS 99
  • 13.10 RIGICON, INC. 100
    • 13.10.1 COMPANY SNAPSHOT 100
    • 13.10.2 PRODUCT PORTFOLIO 100
    • 13.10.3 RECENT DEVELOPMENT 101
  • 13.11 ZEPHYR SURGICAL IMPLANTS. 102
    • 13.11.1 COMPANY SNAPSHOT 102
    • 13.11.2 PRODUCT PORTFOLIO 102
    • 13.11.3 RECENT DEVELOPMENT 102

14 QUESTIONNAIRE 103

15 RELATED REPORTS 106

LIST OF TABLES

  • TABLE 1 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 56
  • TABLE 2 U.K. DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
  • TABLE 3 U.K. ORAL DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
  • TABLE 4 U.K. BRANDED IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 57
  • TABLE 5 U.K. PENILE INJECTIONS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 58
  • TABLE 6 U.K. DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 59
  • TABLE 7 U.K. PENIS PUMPS/VACCUM CONSTRICTION DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 59
  • TABLE 8 U.K. PENILE IMPLANTS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 60
  • TABLE 9 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 65
  • TABLE 10 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 70
  • TABLE 11 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER, 2022-2031 (USD MILLION) 75
  • TABLE 12 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 80

LIST OF FIGURES

  • FIGURE 1 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION 15
  • FIGURE 2 U.K. ERECTILE DYSFUNCTION MARKET: DATA TRIANGULATION 17
  • FIGURE 3 U.K. ERECTILE DYSFUNCTION MARKET: DROC ANALYSIS 18
  • FIGURE 4 U.K. ERECTILE DYSFUNCTION MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 19
  • FIGURE 5 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY RESEARCH ANALYSIS 19
  • FIGURE 6 U.K. ERECTILE DYSFUNCTION MARKET: INTERVIEW DEMOGRAPHICS 20
  • FIGURE 7 U.K. ERECTILE DYSFUNCTION MARKET: MARKET END USER COVERAGE GRID 22
  • FIGURE 8 U.K. ERECTILE DYSFUNCTION MARKET: DBMR MARKET POSITION GRID 24
  • FIGURE 9 U.K. ERECTILE DYSFUNCTION MARKET: VENDOR SHARE ANALYSIS 25
  • FIGURE 10 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION 28
  • FIGURE 11 THE RISING RATES OF CHRONIC DISEASES AMONG MEN IS EXPECTED TO DRIVE THE GROWTH OF THE U.K. ERECTILE DYSFUNCTION MARKET FROM 2024 TO 2031 29
  • FIGURE 12 THE DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.K. ERECTILE DYSFUNCTION MARKET IN 2024 AND 2031 29
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF U.K ERECTILE DYSFUNCTION MARKET 45
  • FIGURE 14 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2022 53
  • FIGURE 15 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION) 54
  • FIGURE 16 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, CAGR (2024-2031) 54
  • FIGURE 17 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, LIFELINE CURVE 55
  • FIGURE 18 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2022 62
  • FIGURE 19 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2024-2031 (USD MILLION) 63
  • FIGURE 20 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, CAGR (2024-2031) 63
  • FIGURE 21 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, LIFELINE CURVE 64
  • FIGURE 22 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2022 67
  • FIGURE 23 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2024-2031 (USD MILLION) 68
  • FIGURE 24 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, CAGR (2024-2031) 68
  • FIGURE 25 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, LIFELINE CURVE 69
  • FIGURE 26 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2023 72
  • FIGURE 27 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2024-2031 (USD MILLION) 73
  • FIGURE 28 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, CAGR (2024-2031) 73
  • FIGURE 29 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, LIFELINE CURVE 74
  • FIGURE 30 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2022 77
  • FIGURE 31 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 78
  • FIGURE 32 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 78
  • FIGURE 33 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 79
  • FIGURE 34 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY SHARE 2023 (%) 81